Subscribe to RSS
DOI: 10.1055/s-0040-1713803
Pre-eclampsia: Universal Screening or Universal Prevention for Low and Middle-Income Settings?
Pré-eclâmpsia: Rastreamento universal ou prevenção universal para países de baixa e média-renda?
Abstract
Pre-eclampsia (PE) is a severe disorder that affects up to 8% of all pregnancies and represents an important cause of maternal and perinatal morbidity and mortality. The screening of the disease is a subject of studies, but the complexity and uncertainties regarding its etiology make this objective a difficult task. In addition, the costs related to screening protocols, the heterogeneity of the most affected populations and the lack of highly effective prevention methods reduce the potential of current available algorithms for screening. Thus, the National Specialized Commission of Hypertension in Pregnancy of the Brazilian Association of Gynecology and Obstetrics Federation (Febrasgo, in the Portuguese acronym) (NSC Hypertension in Pregnancy of the Febrasgo) considers that there are no screening algorithms to be implemented in the country to date and advocates that Aspirin and calcium should be widely used.
Resumo
A Pré-eclâmpsia (PE) é uma doença grave que acomete ∼ 8% das gestações e representa importante causa de morbimortalidade, tanto materna quanto perinatal. O rastreamento da doença é motivo de estudos, porém a complexidade e as incertezas quanto a sua etiologia tornam esse objetivo bastante difícil. Além disso, os custos relacionados com o rastreamento, a heterogeneidade das populações mais afetadas e ainda a falta de métodos de prevenção de grande eficácia reduzem o potencial dos algoritmos de rastreamento. Assim, a Comissão Nacional Especializada sobre Hipertensão na Gravidez da Federação Brasileira das Associações de Ginecologia e Obstetrícia (CNE Hipertensão na Gravidez da FEBRASGO) considera que não há algoritmos de rastreamento que possam ser aplicados no país nesse momento e defende a utilização dos métodos de prevenção como ácido acetilsalicílico e cálcio de maneira ampla.
Contributions
All authors contributed equally for the production of the present manuscript and fulfilled with the criteria for scientific authorship of the International Committee of Medical Journal Editors (ICMJE).
Publication History
Received: 01 April 2020
Accepted: 07 May 2020
Article published online:
29 January 2021
© 2021. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33 (03) 130-137 DOI: 10.1053/j.semperi.2009.02.010.
- 2 Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Análise de Saúde e Vigilância de Doenças Não Transmissíveis [Internet]. Painel de monitoramento da mortalidade materna. 2019 [cited 2019 Dec 10]. Available from: http://svs.aids.gov.br/dantps/centrais-de-conteudos/paineis-de-monitoramento/mortalidade/materna/
- 3 Passini Jr R, Tedesco RP, Marba ST. et al; Brazilian Network of Studies on Reproductive and Perinatal Health. Brazilian multicenter study on prevalence of preterm birth and associated factors. BMC Pregnancy Childbirth 2010; 10: 22 DOI: 10.1186/1471-2393-10-22.
- 4 Souza RT, Cecatti JG, Passini Jr R. et al; Brazilian Multicenter Study on Preterm Birth study group. The burden of provider-initiated preterm birth and associated factors: evidence from the Brazilian Multicenter Study on Preterm Birth (EMIP). PLoS One 2016; 11 (02) e0148244 DOI: 10.1371/journal.pone.0148244.
- 5 Poon LC, Shennan A, Hyett JA. et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet 2019; 145 (Suppl. 01) 1-33 DOI: 10.1002/ijgo.12802.
- 6 Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013; 33 (01) 8-15 DOI: 10.1159/000341264.
- 7 O'Gorman N, Wright D, Syngelaki A. et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol 2016; 214 (01) 103.e1-103.e12 DOI: 10.1016/j.ajog.2015.08.034.
- 8 Rolnik DL, Wright D, Poon LCY. et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol 2017; 50 (04) 492-495 DOI: 10.1002/uog.18816.
- 9 Ramos JGL, Sass N, Costa SHM. Preeclampsia. Rev Bras Ginecol Obstet 2017; 39 (09) 496-512 DOI: 10.1055/s-0037-1604471.
- 10 Peraçoli JC, Borges VTM, Ramos JGL. et al. Pre-eclampsia/Eclampsia. Rev Bras Ginecol Obstet 2019; 41 (05) e1-e2 DOI: 10.1055/s-0040-1702167.
- 11 Townsend R, Khalil A, Premakumar Y. et al; IPPIC Network. Prediction of pre-eclampsia: review of reviews. Ultrasound Obstet Gynecol 2019; 54 (01) 16-27 DOI: 10.1002/uog.20117.
- 12 Di Martino D, Masturzo B, Paracchini S. et al. Comparison of two “a priori” risk assessment algorithms for preeclampsia in Italy: a prospective multicenter study. Arch Gynecol Obstet 2019; 299 (06) 1587-1596 DOI: 10.1007/s00404-019-05146-4.
- 13 Andrikopoulou M, Purisch SE, Handal-Orefice R, Gyamfi-Bannerman C. Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women. Am J Obstet Gynecol 2018; 219 (04) 399.e1-399.e6 DOI: 10.1016/j.ajog.2018.06.011.
- 14 Hoffman MK, Goudar SS, Kodkany BS. et al; ASPIRIN Study Group. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Lancet 2020; 395 (10220): 285-293 DOI: 10.1016/S0140-6736(19)32973-3.
- 15 Mallampati D, Grobman W, Rouse DJ, Werner EF. Strategies for prescribing aspirin to prevent preeclampsia: a cost-effectiveness analysis. Obstet Gynecol 2019; 134 (03) 537-544 DOI: 10.1097/AOG.0000000000003413.
- 16 World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: WHO; 2011
- 17 Camargo EB, Moraes LF, Souza CM. et al. Survey of calcium supplementation to prevent preeclampsia: the gap between evidence and practice in Brazil. BMC Pregnancy Childbirth 2013; 13: 206 DOI: 10.1186/1471-2393-13-206.
- 18 Sun X, Li H, He X. et al. The association between calcium supplement and preeclampsia and gestational hypertension: a systematic review and meta-analysis of randomized trials. Hypertens Pregnancy 2019; 38 (02) 129-139 DOI: 10.1080/10641955.2019.1593445.
- 19 Askie L, Duley L. Associations between the timing and dosing of aspirin prophylaxis and term and preterm pre-eclampsia. BMJ Evid Based Med 2018; ; Jun 7. pii: bmjebm-2018–110931 DOI: 10.1136/bmjebm-2018-110931.
- 20 Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2019; 2019 (10) DOI: 10.1002/14651858.CD004659.pub3.
- 21 Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 2017; 216 (02) 121-128.e2 DOI: 10.1016/j.ajog.2016.10.016.